ANI Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
ANI Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2013-12-31 | 2013-09-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2009-12-31 | 2006-12-31 | 2005-12-31 | 2005-08-29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net revenues | 211,371,000 | 197,122,000 | 190,574,000 | 148,332,000 | 138,040,000 | 137,430,000 | 131,654,000 | 131,829,000 | 116,547,000 | 106,786,000 | 55,538,250 | 83,821,000 | 73,855,000 | 64,477,000 | 38,801,750 | 52,061,000 | 48,625,000 | 54,521,000 | 37,805,750 | 52,979,000 | 48,470,000 | 49,774,000 | 47,966,000 | 51,337,000 | 54,357,000 | 52,887,000 | 57,122,000 | 50,703,000 | 47,268,000 | 46,483,000 | 47,286,000 | 48,164,000 | 44,764,000 | 36,628,000 | 38,205,000 | 38,525,000 | 31,337,000 | 20,555,000 | 18,035,000 | 19,972,000 | 19,516,000 | 18,799,000 | 21,037,000 | 17,387,000 | 6,647,000 | -19,549,570 | 7,836,222 | ||||||||||||||
| operating expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales | 74,615,000 | 73,037,000 | 80,280,000 | 63,075,000 | 57,698,000 | 49,157,000 | 53,420,000 | 48,101,000 | 42,284,000 | 37,708,000 | -101,927,000 | 32,894,000 | 35,294,000 | 34,271,000 | -66,692,000 | 24,413,000 | 22,314,000 | 19,985,000 | -62,480,000 | 20,118,000 | 20,695,000 | 21,804,000 | 17,795,000 | 15,002,000 | 15,632,000 | 14,725,000 | 20,133,000 | 15,605,000 | 16,593,000 | 20,693,000 | 20,446,000 | 21,078,000 | 21,122,000 | 16,386,000 | 16,906,000 | 16,669,000 | 11,795,000 | 3,410,000 | 3,540,000 | 3,260,000 | 3,141,000 | 2,751,000 | 3,673,000 | 3,061,000 | 2,117,000 | -7,066,161.8 | 2,629,119 | ||||||||||||||
| gross profit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| yoy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| qoq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gross margin % | 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 16,535,000 | 10,564,000 | 16,646,000 | 10,128,000 | 7,296,000 | 10,511,000 | 9,867,000 | 11,121,000 | 7,374,000 | 5,924,000 | -16,345,000 | 7,657,000 | 4,165,000 | 5,274,000 | -7,665,000 | 2,456,000 | 2,805,000 | 2,968,000 | -11,721,000 | 2,939,000 | 3,035,000 | 6,344,000 | 4,678,000 | 4,982,000 | 5,773,000 | 4,373,000 | 3,482,000 | 4,667,000 | 5,137,000 | 2,102,000 | 2,651,000 | 2,634,000 | 2,167,000 | 1,618,000 | 135,000 | 1,041,000 | 764,000 | 966,000 | 661,000 | 815,000 | 995,000 | 403,000 | 568,000 | 883,000 | 851,000 | -1,187,455.3 | 453,897 | 972,049 | 13,016,113 | 3,872,736 | 5,398,305 | 5,183,217 | 32,682,207 | 11,500,053 | 11,116,323 | 14,864,420 | |||||
| selling, general, and administrative | 81,771,000 | 76,528,000 | 69,719,000 | 79,075,000 | 52,821,000 | 48,021,000 | 44,462,000 | 42,007,000 | 38,760,000 | 36,468,000 | -77,540,000 | 30,081,000 | 31,958,000 | 28,817,000 | -43,683,000 | 17,181,000 | 18,820,000 | 17,587,000 | -38,419,000 | 15,725,000 | 21,213,000 | 13,683,000 | 14,014,000 | 14,357,000 | 14,188,000 | 13,284,000 | 13,376,000 | 11,769,000 | 9,962,000 | 8,956,000 | 8,885,000 | 8,022,000 | 7,380,000 | 7,293,000 | 7,369,000 | 6,928,000 | 7,628,000 | 5,904,000 | |||||||||||||||||||||||
| depreciation and amortization | 23,281,000 | 22,891,000 | 22,600,000 | 15,748,000 | 14,697,000 | 14,686,000 | 15,194,000 | 15,207,000 | 14,690,000 | 14,700,000 | 10,622,000 | 14,167,000 | 13,764,000 | 14,557,000 | 8,392,000 | 11,346,000 | 11,324,000 | 10,898,000 | 8,434,750 | 11,358,000 | 11,198,000 | 11,183,000 | 9,564,000 | 9,473,000 | 9,472,000 | 16,103,000 | 8,686,000 | 8,548,000 | 8,313,000 | 8,195,000 | 7,022,000 | 7,099,000 | 7,101,000 | 6,706,000 | 5,812,000 | 5,966,000 | 5,956,000 | 4,609,000 | 2,111,000 | 2,047,000 | 1,415,000 | 1,327,000 | 1,282,000 | 1,187,000 | 706,000 | -672,824.4 | 381,699 | ||||||||||||||
| contingent consideration fair value adjustment | 1,277,000 | -12,092,000 | -1,893,000 | 825,000 | 359,000 | 90,000 | 1,985,000 | -2,555,000 | 1,035,000 | 961,000 | 533,500 | 2,476,000 | -1,095,000 | 753,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of building | -5,347,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 197,479,000 | 170,928,000 | 194,952,000 | 168,851,000 | 132,871,000 | 117,118,000 | 124,928,000 | 113,881,000 | 104,145,000 | 96,891,000 | 64,814,000 | 88,816,000 | 86,768,000 | 83,672,000 | 42,819,250 | 55,623,000 | 64,178,000 | 51,476,000 | 41,892,500 | 50,177,000 | 59,777,000 | 57,616,000 | 52,637,000 | 44,009,000 | 45,065,000 | 48,485,000 | 45,677,000 | 40,589,000 | 40,005,000 | 39,946,000 | 39,907,000 | 38,833,000 | 37,770,000 | 32,003,000 | 36,907,000 | 30,604,000 | 26,143,000 | 14,889,000 | 11,767,000 | 11,521,000 | 11,102,000 | 9,232,000 | 10,265,000 | 9,188,000 | 9,107,000 | 5,527,873.25 | 7,025,931 | ||||||||||||||
| operating income | 13,892,000 | 26,194,000 | -4,378,000 | -20,519,000 | 5,169,000 | 20,312,000 | 6,726,000 | 17,948,000 | 12,402,000 | 9,895,000 | -9,275,750 | -4,995,000 | -12,913,000 | -15,553,000 | -4,671,000 | 7,328,000 | 9,292,000 | 4,402,000 | 11,445,000 | 10,114,000 | 7,263,000 | 6,537,000 | 7,379,000 | 9,331,000 | 6,994,000 | 4,625,000 | 1,298,000 | 7,921,000 | 5,194,000 | 5,666,000 | 6,608,000 | 8,451,000 | 9,567,000 | ||||||||||||||||||||||||||||
| yoy | 168.76% | 28.96% | -165.09% | -214.32% | -58.32% | 105.28% | -172.51% | -459.32% | -196.04% | -16.97% | -140.81% | -27.55% | 27.94% | -32.66% | 55.10% | 8.39% | 3.85% | 41.34% | 468.49% | 17.80% | 34.66% | -18.37% | -80.36% | -6.27% | -40.78% | ||||||||||||||||||||||||||||||||||||
| qoq | -46.96% | -698.31% | -78.66% | -496.96% | -74.55% | 201.99% | -62.53% | 44.72% | 25.34% | -206.68% | 85.70% | -61.32% | -163.74% | -21.14% | 111.09% | -61.54% | 13.16% | 39.25% | 11.11% | -11.41% | -20.92% | 33.41% | 51.22% | 256.32% | -83.61% | 52.50% | -8.33% | -14.26% | -21.81% | ||||||||||||||||||||||||||||||||
| operating margin % | 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | 1,739,000 | 198,000 | -1,378,000 | -2,535,000 | -88,000 | -32,000 | -33,000 | -39,000 | -53,000 | -34,000 | -89,000 | -413,250 | -1,071,000 | -67,000 | -83,750 | -229,000 | -130,000 | -30,000 | -61,000 | -19,000 | 2,000 | 68,000 | -39,000 | 13,000 | 2,000 | 13,000 | |||||||||||||||||||||||||||||||||||
| unrealized gain on investment in equity securities | 332,000 | -921,000 | -1,991,000 | 1,355,000 | -2,712,000 | 9,655,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -5,438,000 | -5,484,000 | -6,015,000 | -2,331,000 | -4,656,000 | -4,600,000 | -5,746,000 | -6,398,000 | -7,100,000 | -7,696,000 | -5,136,500 | -7,264,000 | -6,669,000 | -6,613,000 | -1,870,500 | -2,497,000 | -2,531,000 | -2,454,000 | -1,724,500 | -2,510,000 | -2,356,000 | -2,032,000 | -2,870,000 | -3,336,000 | -3,406,000 | -3,354,000 | -3,626,000 | -3,768,000 | -3,730,000 | -3,634,000 | -3,026,000 | -3,052,000 | -3,025,000 | -2,932,000 | -2,859,000 | -2,856,000 | -2,830,000 | -2,782,000 | -2,725,000 | 466,903.6 | |||||||||||||||||||||
| income before income tax expense | 10,525,000 | 19,987,000 | 25,335,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | 1,976,000 | 4,306,000 | 7,128,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | 8,549,000 | 15,681,000 | -10,276,000 | -24,166,000 | -2,287,000 | 18,207,000 | 1,155,000 | 9,940,000 | 6,245,000 | 1,439,000 | -10,913,250 | -8,600,000 | -14,923,000 | -14,106,000 | 2,732,250 | 3,895,000 | 6,585,000 | 449,000 | 2,516,000 | 5,037,000 | 2,777,000 | 2,250,000 | 2,138,250 | 4,720,000 | 2,681,000 | 1,152,000 | -1,080,000 | 2,543,000 | 1,125,000 | 1,346,000 | 2,876,000 | 4,559,000 | 4,369,000 | -2,290,649 | -21,595,924 | -6,121,815 | -7,344,116 | -10,264,477 | -38,874,813 | -12,733,691 | -14,975,231 | -17,250,676 | |||||||||||||||||||
| yoy | -473.81% | -13.87% | -989.70% | -343.12% | -136.62% | 1165.25% | -110.58% | -215.58% | -141.85% | 5.79% | 8.59% | -22.67% | 137.13% | -80.04% | 17.67% | 6.72% | 3.58% | 95.31% | -297.99% | 85.61% | 138.31% | -14.41% | -137.55% | -44.22% | -69.19% | -77.68% | -44.45% | -51.92% | -50.96% | -40.50% | |||||||||||||||||||||||||||||||
| qoq | -45.48% | -252.60% | -57.48% | 956.67% | -112.56% | 1476.36% | -88.38% | 59.17% | 333.98% | -113.19% | 26.90% | -42.37% | -29.85% | -40.85% | 1366.59% | -82.15% | -50.05% | 81.38% | 23.42% | 5.23% | -54.70% | 76.05% | 132.73% | -206.67% | -142.47% | 126.04% | -16.42% | -53.20% | -36.92% | -89.39% | 252.77% | -16.64% | -28.45% | -73.60% | 205.29% | -14.97% | -13.19% | ||||||||||||||||||||||||
| net income margin % | 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| dividends on series a convertible preferred stock | -407,000 | -406,000 | -406,000 | -406,000 | -407,000 | -406,000 | -406,000 | -406,000 | -407,000 | -406,000 | -304,500 | -406,000 | -407,000 | -405,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| net income available to common shareholders | 8,142,000 | 15,275,000 | -10,682,000 | -24,572,000 | -2,694,000 | 17,801,000 | 749,000 | 9,534,000 | 5,838,000 | 1,033,000 | -11,217,750 | -9,006,000 | -15,330,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted income per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic income per share | 0.37 | 0.7 | -0.55 | -1.27 | -0.14 | 0.84 | 0.02 | 0.46 | 0.3 | 0.06 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted income per share | 0.36 | 0.69 | -0.55 | -1.27 | -0.14 | 0.82 | 0.02 | 0.45 | 0.29 | 0.06 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| basic weighted-average shares outstanding | 19,834 | 19,607 | 19,318 | 19,404 | 19,321 | 19,099 | 18,001 | 18,883 | 17,688 | 16,392 | 16,303 | 16,272 | 16,137 | 12,107 | 12,085 | 12,004 | 11,991 | 11,967 | 11,902 | 11,841 | 11,879 | 11,851 | 11,747 | 11,677 | 11,706 | 11,679 | 11,589 | 11,547 | 11,553 | 11,546 | 11,527 | 11,445 | 11,465 | 11,402 | 11,395 | 11,370 | 11,384 | 11,344 | 11,326 | 10,941 | 11,235 | 11,233 | |||||||||||||||||||
| diluted weighted-average shares outstanding | 20,308 | 20,046 | 19,318 | 19,404 | 19,321 | 19,422 | 18,194 | 19,125 | 17,855 | 16,531 | 16,303 | 16,272 | 16,137 | 12,107 | 12,085 | 12,017 | 12,003 | 11,967 | 11,902 | 12,040 | 12,085 | 12,269 | 11,823 | 11,772 | 11,804 | 11,789 | 11,706 | 11,547 | 11,677 | 11,667 | 11,653 | 11,573 | 11,625 | 11,541 | 11,489 | 11,557 | 11,563 | 11,549 | 11,562 | 11,053 | 11,302 | 11,233 | |||||||||||||||||||
| restructuring activities | 2,000 | 1,130,000 | 1,027,750 | 1,541,000 | 2,570,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -7,468,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax (benefit) expense | -2,112,500 | -31,498,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -3,486,000 | -7,332,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax benefit | -2,287,000 | 4,731,250 | 11,511,000 | 5,249,000 | 2,165,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 2,394,000 | -1,571,000 | 996,000 | -726,000 | 20,713 | 82,852 | 121,791 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| intangible asset impairment charge | 28,000 | 112,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| legal settlement expense | 2,100,000 | 8,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| purified cortrophin gel pre-launch charges | 195,000 | 227,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income/(expense) | 178,000 | 37,000 | 764,000 | 10,000 | 46,000 | -17,750 | 20,000 | -3,000 | 95,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit for income taxes | -14,234,250 | -12,222,000 | -18,818,000 | -18,151,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit for income taxes | 3,321,000 | 3,622,000 | 3,895,000 | 5,767,000 | 1,684,500 | 2,683,000 | 4,045,000 | 10,000 | 1,443,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted loss per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic loss per share | -0.69 | -0.55 | -0.94 | -1.17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted loss per share | -0.69 | -0.55 | -0.94 | -1.17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating (loss)/income | -19,195,000 | -4,017,500 | -3,562,000 | -11,307,000 | -7,842,000 | -2,460,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (loss)/income before benefit for income taxes | -25,897,000 | -6,301,250 | -7,130,000 | -13,779,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net (loss)/income | -20,130,000 | -4,616,750 | -4,447,000 | -12,336,000 | -7,011,000 | -2,363,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net (loss)/income available to common shareholders | -20,535,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted (loss)/earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic (loss)/earnings per share | -1.27 | -0.383 | -0.37 | -1.03 | -0.59 | -0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted (loss)/earnings per share | -1.27 | -0.383 | -0.37 | -1.03 | -0.59 | -0.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cortrophin pre-launch charges | 515,000 | 38,000 | 2,068,750 | 37,000 | 3,636,000 | 4,602,000 | 6,511,000 | 195,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating income/ | 3,045,000 | -4,086,750 | 2,802,000 | 8,414,000 | 2,308,500 | 8,199,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other (expense)/income | -515,000 | -116,000 | -111,000 | -33,000 | -18,000 | -43,000 | -21,000 | -12,000 | 10,000 | -28,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) before benefit for income taxes | 76,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income/ | 86,000 | -4,728,250 | 434,000 | 3,571,000 | 1,935,500 | 6,746,000 | -782,982.25 | 1,191,043 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted earnings/(loss) per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings/(loss) per share | 0.01 | -0.395 | 0.04 | 0.31 | 0.178 | 0.59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted earnings/(loss) per share | 0.01 | -0.395 | 0.04 | 0.31 | 0.175 | 0.59 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) before benefit/(provision) for income taxes | -5,895,000 | 63,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit/(provision) for income taxes | 1,166,750 | 371,000 | 2,853,000 | 653,000 | 133,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (loss)/income before benefit/(provision) for income taxes | -9,864,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before (provision)/benefit for income taxes | 2,702,250 | 3,959,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (provision)/benefit for income taxes | 30,000 | -64,000 | -394,250 | -1,545,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share | 0.228 | 0.32 | 0.55 | 0.04 | 0.213 | 0.43 | 0.24 | 0.19 | 0.185 | 0.41 | 0.23 | 0.1 | -0.1 | 0.22 | 0.1 | 0.12 | 0.273 | 0.4 | 0.38 | ||||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share | 0.223 | 0.32 | 0.53 | 0.04 | 0.213 | 0.42 | 0.23 | 0.19 | 0.183 | 0.4 | 0.23 | 0.1 | -0.09 | 0.22 | 0.1 | 0.12 | 0.268 | 0.39 | 0.38 | ||||||||||||||||||||||||||||||||||||||||||
| income before benefit/(provision) for income taxes | 5,932,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit from income taxes | 918,000 | 7,340,000 | 6,366,000 | 3,503,000 | 2,842,000 | 4,350,000 | 6,374,000 | 3,950,000 | 1,675,000 | 2,570,500 | 5,044,000 | 2,352,000 | 2,886,000 | 4,558,000 | 5,657,000 | 6,910,000 | |||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | -469,000 | -1,910,000 | -1,329,000 | -726,000 | -592,000 | -13,979,000 | -1,654,000 | -1,269,000 | -523,000 | -1,317,000 | -2,501,000 | -1,227,000 | -1,540,000 | -1,433,250 | -1,098,000 | -2,541,000 | |||||||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 3,925,250 | 5,399,000 | 5,551,000 | 4,751,000 | 4,742,000 | 4,057,000 | 5,433,000 | -4,261,127.5 | 1,750,734 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest (expense)/income | -2,060,000 | -2,766,000 | -2,749,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) before benefit from/benefit from income taxes | 5,665,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (benefit from)/benefit from income taxes | -2,094,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income/ | 88,000 | 82,000 | -84,098.25 | 147,563 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income/ | 3,250 | 10,000 | 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) before benefit from income taxes | 2,329,750 | 8,291,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income/(loss) from continuing operations | 1,935,500 | 6,746,000 | -820,566.5 | 1,040,706 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| discontinued operation | 0.01 | 0.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on discontinued operation, net of benefit from income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| computation of income/(loss) from continuing operations attributable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| to common stockholders and participating securities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preferred stock dividends | -1,243,549.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) from continuing operations attributable to common stockholders and participating securities | 21,005,000 | 6,746,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| continuing operations | 1.9 | 0.59 | -0.578 | 0.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (loss)/income before benefit from income taxes | -2,496,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| computation of (loss)/income attributable to common stockholders: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (loss)/income attributable to common stockholders | -2,363,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| salaries and benefits | 2,174,909.5 | 1,729,066 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| freight | 56,047.25 | 81,416 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating income/(loss) from continuing operations | -640,455.75 | 810,291 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income/(loss) from continuing operations before income tax benefit | -841,279.5 | 957,854 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on discontinued operation, net of tax | 37,584.25 | 150,337 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| computation of income/(loss) from continuing operationsattributable to common stockholders: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income/(loss) from continuing operations attributable to common stockholders | -2,064,116.25 | 1,040,706 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted income/(loss) per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted income/(loss) per share | -0.568 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted weighted-average shares outstanding | 9,480,206 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue | 145,040 | 2,190,353 | 110,383 | 108,780 | 114,000 | 252,376 | 182,784 | 81,003 | 57,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| yoy | 27.23% | 767.89% | -39.61% | 34.29% | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| qoq | -93.38% | 1884.32% | 1.47% | -4.58% | -54.83% | 38.07% | 125.65% | 42.11% | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 1,949,114 | 6,682,659 | 1,546,864 | 1,948,995 | 1,831,852 | 5,306,222 | 1,675,268 | 1,989,103 | 1,593,557 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income — convertible note fair value adjustment | 15,953 | 115,750 | 463,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income — interest expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income - interest income | 1,860 | 469.25 | 1,877 | 1,431 | 1,992 | 379 | 1,516 | 1,711 | 3,245 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income — gain on sale of intellectual property | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share | -0.09 | -1 | -0.27 | -0.36 | -0.09 | -0.4 | -0.12 | -0.16 | -0.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares and common equivalent shares outstanding | 24,487,451 | 21,757,906 | 22,921,176 | 20,202,737 | 116,266,613 | 98,385,709 | 104,439,220 | 93,985,347 | 84,764,512 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income – convertible note fair value adjustment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income – interest expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income — investment impairment loss |
We provide you with 20 years income statements for ANI Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANI Pharmaceuticals stock. Explore the full financial landscape of ANI Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about ANI Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.